Daiichi Buys Biotech Antibody Technology From U.S. Firm
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo bought compound-combining technology from Seattle Genetics, a U.S. start-up biotech, for $4 million plus future payments if Daiichi brings drugs to market. Eventually, the Japanese drug maker plans to handle the biotech process on its own, but in the interim is to send antibodies and compounds to Seattle to have them combined and returned to Japan for research and development. Daiichi is interested in cancer-fighting compounds to combine with antibody drugs to make treatments more effective. (Click here for more - a subscripiton may be required
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.